J Neurogastroenterol Motil.  2016 Jul;22(3):412-422. 10.5056/jnm16004.

Use of Prucalopride for Chronic Constipation: A Systematic Review and Meta-analysis of Published Randomized, Controlled Trials

• Sajid MS
• Hebbar M
• Baig MK
• Li A
• Philipose

• KMID: 2327946
• DOI: http://doi.org/10.5056/jnm16004

Abstract

This article highlights the role of prucalopride in the management of chronic constipation based upon the principles of meta-analysis using data reported in the published randomized, controlled trials. Sixteen randomized, controlled trials on 3943 patients reported the effectiveness of prucalopride in patients with chronic constipation. Prucalopride successfully increased the frequency of spontaneous bowel movements per week in all variable doses of 1 mg (standardized mean difference [SMD], 0.42 [95% CI, 0.18-0.66; P = 0.006]), 2 mg (SMD, 0.34 [95% CI, 0.11-0.56; P = 0.003]), and 4 mg (SMD, 0.33 [95% CI, 0.22-0.44; P = 0.00001]). The risks of adverse events or side effects such as headache, abdominal cramps, excessive flatulence, dizziness, diarrhea, and rash were higher (odds ratio, 1.70 [95% CI, 1.27 to -2.27; P = 0.0004]) in prucalopride group. Prucalopride is clinically a beneficial pharmacotherapy for chronic constipation and its routine use may be considered in patients with chronic simple laxative-resistant constipation.

Keyword

Constipation; Functional bowel disorders; Laxatives; Prucalopride; Secondary constipation

MeSH Terms

Colic
Constipation*
Diarrhea
Dizziness
Drug Therapy
Exanthema
Flatulence
Headache
Humans
Laxatives
Laxatives